Answers are grounded in this paper and cite their sources.
Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD) is a potentially fatal complication of immunosuppression post haematopoietic stem cell and solid organ transplantation.While it is clear that profound T-cell depletion is a prerequisite for the outgrowth of EBV-infected B cells, cofactors, such as imbalance in cytokines and chemokines, are probably important.There is no consensus on the optimal treatment for PTLD and most have associated toxicity.Early treatment or prophylaxis is safer and more effective than treatment of advanced disease; however, the risks of treatment must be weighed against the risk of developing disease.Therefore, effective treatments with low toxicity as well as sensitive and specific tests for the early identification of patients who will develop PTLD are required.Recent studies with the humanized anti-B-cell antibody Rituximab and the adoptive transfer of EBVspecific cytotoxic T lymphocytes have suggested that these treatments may be effective and non-toxic.Polymerase chain reaction techniques allow for sensitive monitoring of EBV-DNA load and selection of high-risk patients.However, as patients with a high virus load do not always develop PTLD, additional analysis of virus-specific T cellmediated immunity may increase the specificity of the diagnosis.
No takes yet. Share an insight, caveat, or question.
Straathof et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: